Hepatitis C Virus Infection Terminated Phase 2 Trials for Velpatasvir (DB11613)

Indication	Status	Phase
DBCOND0033268 (Hepatitis C Virus Infection)	Terminated	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03820258	Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection	Treatment	Sofosbuvir (DB08934) Velpatasvir (DB11613) Voxilaprevir (DB12026)